北京同仁堂集团，最新声明！

Core Viewpoint - Beijing Tongrentang Group has issued an apology regarding the recent controversy surrounding "Antarctic krill oil," acknowledging the damage to consumer rights and emphasizing their commitment to consumer protection and brand integrity [1][3]. Group 1: Company Response - The company has initiated a zero-tolerance brand management action, including a comprehensive investigation into the involved products and the immediate removal of the products from the market [2]. - Legal actions will be pursued against the involved parties, including Sichuan Health and Harbo Pharmaceutical, for trademark infringement and misleading consumers [2][3]. - The company will conduct a thorough review of brand usage across its subsidiaries to eliminate any unauthorized or misleading use of the "Tongrentang" brand [3]. Group 2: Product Controversy - A product labeled as "99% high-purity Antarctic krill oil" was found to have a phospholipid content of 0%, despite claims of 43%, raising concerns of false advertising [10][14]. - The product in question is produced by Anhui Harbo Pharmaceutical and distributed by Beijing Tongrentang (Sichuan) Health Pharmaceutical, which is a subsidiary of Tongrentang Group [14]. - The Shanghai Consumer Protection Committee is taking action to address the alleged fraudulent behavior and protect consumer rights [10][14]. Group 3: Industry Context - Antarctic krill oil is marketed for its health benefits, including brain function improvement and immune enhancement, leading to its popularity in the market [8]. - The production methods of krill oil can vary, affecting phospholipid content, but any discrepancies between advertised and actual content can lead to consumer trust issues [12][13][14]. - The practice of allowing subsidiaries to use the main brand's trademark can reduce costs and increase revenue but may dilute brand value if not managed properly [14].